CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.

Abstract

The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors.

DOI: 10.1158/1078-0432.CCR-14-2556

9 Figures and Tables

Cite this paper

@article{Kelly2015CCR2A, title={CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.}, author={William Kevin Kelly and Paul Marks and Victoria M. Richon}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2015}, volume={21 10}, pages={2198-200} }